4.8 Article

Designing Core-Shell Gold and Selenium Nanocomposites for Cancer Radiochemotherapy

期刊

ACS NANO
卷 11, 期 5, 页码 4848-4858

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsnano.7b01346

关键词

nanocomposites; targeting; radiochemotherapy; radiosentization; cancer therapy

资金

  1. Science Foundation for Distinguished Young Scholars of Guangdong Province [2013050014667]
  2. Natural Science Foundation of China [21371076]
  3. National High-level personnel of special support program [2014189]
  4. YangFan Innovative & Entepreneurial Research Team Project [201312H05]
  5. Guangdong Special Support Program
  6. Guangdong Frontier Key Technological Innovation Special Funds [2014B050505012]
  7. Fundamental Research Funds for the Central Universities
  8. Hong Kong Research Grants Council (RGC) General Research Funds (GRF) [City U11301215]

向作者/读者索取更多资源

Radiotherapy is an important regime for treating malignant tumors. There is interest in the development of radiosensitizers to increase the local treatment efficacy under a relatively low and safe radiation dose. In this study, we designed Au@Se-R/A nanocomposites (Au@Se-R/A NCs) as nano-radiosensitizer to realize synergistic radiochemotherapy based on the radiotherapy sensitization property of Au nanorods (NRs) and antitumor activity of Se NPs. In vitro studies show that the combined treatment of A375 melanoma cells in culture with NCs and X-ray induces cell apoptosis through alteration in expression of p53 and DNA-damaging genes and triggers intracellular ROS overproduction, leading to greatly enhanced anticancer efficacy. Further studies using clinically used radiotherapy equipment demonstrate that the combined treatment of NCs and X-ray significantly inhibits the tumor growth in vivo and shows negligible acute toxicity to the major organs. Taken together, this study provides a strategy for clinical translation application of nanomedicne in cancer radiochemotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据